# Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure

> **NCT02788227** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 99 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** rVSV-Zebov GP vaccine

## Key facts

- **NCT ID:** NCT02788227
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-14
- **Primary completion:** 2025-06-17
- **Final completion:** 2025-06-17
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02788227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02788227, "Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02788227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*